Nasdaq · CIK 0000874015 · PHARMACEUTICAL PREPARATIONS
Ionis Pharmaceuticals, Inc.
IONS chart by TradingView
PRICE HISTORY
LIVE · NASDAQIONS chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $0.9B
- EBITDA
- $-0.4B
- FREE CASH FLOW
- $-0.3B
- EPS
- $-2.38
- GROSS MARGIN
- 98.31%
- ROIC
- -20.32%
Q2 FY26ENDED JUN 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 40 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
—
+96%20.0x18080.4x
⤢
P / SALES (TTM)
15.0x
-21%5.3x19.0x
⤢
P / BOOK
29.8x
-8%4.8x59.3x
⤢
EV / EBITDA (TTM)
—
⤢
EV / REVENUE (TTM)
—
+39%8.7x14.9x
⤢
FCF YIELD (TTM)
-4.28%
-1.4pp-11.59%9.85%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$0.3B
+142%⤢
EBITDA (DERIVED)
$-0.1B
-646%⤢
NET INCOME
$-0.1B
-1660%⤢
EPS (DILUTED)
$-0.69
-1263%⤢
REVENUE GROWTH YOY
-40.73%
-166.5pp-65.48%261.65%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
205.06%
+184.1pp-331.01%419.21%
⤢
RETURN ON CAPITAL
—
-2.0pp-29.81%-18.32%
⤢
RETURN ON EQUITY (TTM)
-128.53%
+3.1pp-138.70%32.16%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN98.98%
OPERATING MARGIN-38.18%
NET MARGIN-42.79%
FCF MARGIN205.06%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$0.5B
+2265%⤢
STOCK-BASED COMP
$0.0B
+159%⤢
CAPITAL EXPENDITURE
$0.0B
+1431%⤢
SHARES OUTSTANDING
0.17B
+34%⤢
DIVIDEND / SHARE
—
BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$0.4B
+315%⤢
TOTAL DEBT
—
+50%⤢
DEBT / EBITDA (TTM)
—
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 107.46%INSIDERS 0.61%OTHER / RETAIL 0.00%717 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| FMR, LLC | 14.78% | 24.6M | $1.39B | +2.0% |
| Capital World Investors | 12.75% | 21.2M | $1.20B | +18.0% |
| Blackrock Inc. | 6.28% | 10.4M | $590.6M | -1.9% |
| Vanguard Portfolio Management LLC | 4.70% | 7.8M | $441.7M | NEW |
| Vanguard Capital Management LLC | 4.28% | 7.1M | $402.6M | NEW |
| Wellington Management Group, LLP | 3.85% | 6.4M | $361.5M | +2.1% |
| T. Rowe Price Investment Management, Inc. | 3.71% | 6.2M | $348.4M | -32.4% |
| Two Sigma Investments, LP | 3.52% | 5.9M | $331.3M | +120.3% |
| State Street Corporation | 2.40% | 4.0M | $226.0M | +0.5% |
| Geode Capital Management, LLC | 2.40% | 4.0M | $225.4M | +26.5% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.